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The first step in metabolic activation of mutagenic and carcinogenic heterocyclic amines has been
elucidated to beN-hydroxylation by cytochrome P-448. N-Hydroxyamino compounds are further activated
to form N-O-acyl derivatives that readily react with DNA. The adducts between the metabolites ofTrp-P-
2andGlu-P-1 andDNAwereshowntohaveaC8-guanylamino structure. InthecaseofGlu-P-1, modification
of guanine in GC clusters occurred preferentially. Glutathione transferases and myeloperoxidase were
shown to inactivate some heterocyclic amines or their active metabolites. Hemin and fatty acids bind to
and inactivate them. Fibers and other factors from vegetables also workto inactivate heterocyclic amines.
Nitrite at low pH also degraded some heterocyclic amines, but those with an imidazole moiety were
resistant. Glu-P-1 induced intestinal tumors in a high incidence when fed orally to rats. When 14C-Glu-
P-1 was administered by gavage into rats about 50% and 35% were excreted into feces and urine, respec-
tively, within 24 hr. When the bile was collected, around 60% of radioactivity was excreted into it within
24 hr. In the bile, N-acetyl-Glu-P-1 was identified as one of the metabolites of Glu-P-1. It showed a
mutagenic activity ofabout one fourth that of Glu-P-1 with S9 mix. Some radioactivity was also detected
in the blood. At 24 hr after administration, most ofthe radioactivity was found to be bound to erythrocyte
,B-globins and serum proteins including albumin.
Metabolic Activation of Pyrolysis
Mutagens
Most of these studies have been done with Trp-P-2
and Glu-P-1 by using S9 or microsomal fraction of rat
liver or areconstituted system including cytochrome P-
450 by the groups of Kato and Shudo (1-6). The first
step in activation is N-hydroxylation, and for this cy-
tochrome P-448 induced by polychlorinated biphenyls
or 3-methylcholanthrene was found by Ishii et al. (1,2)
to be most effective. This was confirmed also by Wa-
tanabe et al. (7) using antibodies against P-450.
Hashimoto et al. found that the N-hydroxyamino de-
rivative of Trp-P-2 reacted with DNA to some extent
but its N-O-acyl derivative reacted more with DNA (5).
In the case of Glu-P-1 also, the N-O-acyl derivative is
regarded as an ultimate form which reacts with DNA
(4).t The structures ofthe adducts ofTrp-P-2 and Glu-
P-1 have been elucidated to be C8-guanylamino deriv-
atives by Hashimoto et al. (4,5). They showed that this
modification of guanine by Glu-P-1 occurred preferen-
tially in GC clusters in the fragment ofpBR322 plasmid
DNA (8). This observation is interesting because the
hot spot for reverse mutation in Salmonella typhimu-
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rium TA 98 is also GC clusters as was shown by Ames
et al. (9). The N-hydroxyamino derivative of 2-amino-
3-methylimidazo [4,5-f] quinoline (IQ) was also isolated
by Okamoto et al. (10) and Yamazoe et al. (11). N-
Hydroxylationasastepofactivationwasalsosuggested
for 2-amino-9H-pyrido [2, 3-b] indole (AaLC) by Niwa et
al. (12).
For the further activation ofN-hydroxy-Trp-P-2, the
involvement of seryl or propyl tRNA synthetase has
been proposed by Yamazoe et al. (13,14) as in the case
of4-hydroxy-aminoquinoline 1-oxide (15). Acetyl-CoA-
dependent enzyme has also been shown by Shinohara
et al. (16) to activate N-hydroxy-Trp-P-2 and N-hy-
droxy-Glu-P-1 to bind to DNA. The involvement ofsul-
fotransferase in the activation of various heterocyclic
amines was tested by Nagao et al. (17) by the addition
ofpentachlorophenol, aninhibitorofthis enzyme, to the
system of mutation assay. The mutagenicity of Glu-P-
1 and IQ was markedly inhibited but that of Trp-P-2
was not. These results suggested that the ultimate
forms of Glu-P-1 and IQ are sulfate esters of their N-
hydroxy derivatives, but for the further activation of
N-hydroxy-Trp-P-2, other mechanisms such as the in-
volvement acetyl-transferases or prolyl-tRNA synthe-
tase are responsible. The pathway of metabolic acti-
vation ofheterocyclic amines as represented by Trp-P-
2 is schematically illustrated in Figure 1.SATO ETAL.
Table 1. Abbreviations used.
Abbreviation
Trp-P-2
Glu-P-1
N-Acetyl-Glu-P-1
IQ
AaC
Trp-P-1
Glu-P-2
MeAaC
Phe-P-1
MeIQ
MeIQx
4,8-DiMeIQx
7,8-DiMeIQx
CH, CHM
N PNM 4 NOH H
Trp-P- 2 N-hydroxy-Trp-P-2
CM, CM,
HN N eNH ~4 N% H XNL.NNH
NO-CFTrp-P-2
R: Prolyl
: Acdyl Trp-P-2-DNA adduct
FIGURE 1. Pathway ofmetabolic activation of Trp-P-2.
Inactivation of Pyrolysis Mutagens
The mode of metabolic inactivation of heterocyclic
amines is not fully elucidated. Glutathione transferases
have been found by Saito et al. (18) to catalyze the
conjugation of glutathione with N-hydroxy-Trp-P-2 to
form some detoxicated products. On the other hand,
there are some reports on the factors which inhibit the
activityofheterocyclic amines. Heminandotherpyrrole
pigments (19) andfattyacidssuchasoleicacidorlinoleic
acid (20) were shown by Hayatsu and his colleagues to
inhibit the mutagenicity ofheterocyclic amines by bind-
ing to them. Lipid peroxides were shown by Saito et
al. (21) to convert an active metabolite of Trp-P-2 to
nonreactive forms. Yamada et al. (22) found that mye-
loperoxidase degraded Trp-P-1, Trp-P-2, Glu-P-1, and
AaC with loss oftheir mutagenicity in the presence of
hydrogen peroxide.
Other than the above-mentioned endogenous factors
there are some exogenous factors reported to inactive
heterocycic amines. They are lactoperoxidase (22) and
peroxidases of plant origin (22,23). Vegetable fibers
work to absorb heterocyclic amines and inhibit their
mutagenicity (24,25). An irreversible inactivation of
Trp-P-1 andTrp-P-2byafactorwithamolecularweight
higherthan 300,000 isolated fromburdock wasreported
byMorita et al. (26). Nitrite underacidicconditions was
found by Tsuda et al. (27,28) to inactivate some het-
erocycic amines including Trp-P-1, Trp-P-2, Glu-P-1,
Glu-P-2, AaC, MeAaC and Phe-P-1 (non-IQ type)
through deamination. However, IQ, MeIQ, MeIQx, 4,8-
DiMeIQx and 7,8-DiMeIQx (IQ type) are resistant to
Compound
3-Amino-l-methyl-5H-pyrido[4,3-b]indole
2-Amino-6-methyldipyrido[1,2-a:3',2'-d]imidazole
2-N-Acetylamino-6-methyldipyrido[1,2-a:3',2'-d]imidazole
2-Amino-3-methylimidazo[4,5-flquinoline
2-Amino-9H-pyrido[2,3-b]indole or 2-amino-ox-carboline
3-Amino-1,4-dimethyl-5H-pyrido[4,3-b]indole
2-Aminodipyrido[1,2-a:3',2'-d]imidazole
2-Amino-3-methyl-9H-pyrido[2,3-b]indole or 2-amino-3-methyl-ax-carboline
2-Amino-5-phenylpyridine
2-Amino-3,4-dimethylimidazo[4,5-flquinoline
2-Amino-3,8-dimethylimidazo[4,5-JXquinoxaline
2-Amino-3,4,8-trimethylimidazo[4,5-flquinoxaline
2-Amino-3,7,8-trimethylimidazo[4,5-flquinoxaline
this treatment. This resistance is due to protonation
under acidic conditions of the amino moiety of the IQ
class of mutagens.
Inhibition of mutagenicity of Trp-P-1, Trp-P-2, Glu-
P-1, and Glu-P-2 by retinol was reported by Busk et al.
(29). Retinol in this case was interpreted to inhibit the
metabolic activation of these heterocyclic amines. Co-
baltous chloride was shown by Mochizuki and Kada (30)
to inhibit the mutation of S. typhimurium TA 98 and
TA 1538 by Trp-P-1. In this case cobaltous chloride did
not seemtoworkdirectly onTrp-P-1 oronitsmetabolic
activation but to inhibit the mutagenicity by improving
the fidelity in DNA synthesis in the bacteria.
Metabolism of Glu-P-1 in the Rat
Glu-P-1, when fed to rats induced tumors in the liver,
small and large intestines and Zymbal gland (31). The
incidence ofintestinal tumors was relatively high. Thus
we were interested in the distribution and excretion of
'4C-Glu-P-1 which was administered orally to rats and
its metabolites in the bile. [Imidazole-'4C]-Glu-P-1 was
introduced into the stomach of male F344 rats by a
gastric tube at 0.3 mCi/20.8 mg/kg body weight. At
various times after administration various organs, ur-
ine, feces and blood were taken and theirradioactivities
were assayed. The radioactivity per unit wet weight of
organ was highest in the liver through the observation
period up to 48 hr, followed by the kidney. By 48 hr
the radioactivity in these two organs had decreased to
one fourth ofthe level at 5 hr. Five hours after admin-
istration, radioactivity comparable tothatinthe kidney
was found in the mucosa of the small and large intes-
tines. However, inthesetissues, the activity remaining
at 24 hr and 48 hr was very low. Cold ethanol-precip-
itableradioactivitiesintheliverhomogenatewereabout
one halfthat ofthe total activity at 5 hr and 75% at 48
hr. In the kidney they were 22% and 50% at 5 hr and
48 hr, respectively. In other organs some cold ethanol-
precipitable radioactivity also remained, but actual
counts were very low compared to those in the liver
and kidney. The excretion of radioactivity into urine
increased gradually up to 24 hr, when 35% of the ad-
ministered amount had been excreted. Relatively high
radioactivities bound to macromolecules in the liver
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FIGURE 2. Excretions of radioactivity and mutagenicity after
administration of '4C-Glu-P-1 by gavage into a rat. Mutagenicity
was assayed by S. typhimurium TA 98 with S9 mix.
throughout the observation period may be related to
the high incidence ofliver tumor induction by this het-
erocyclic amine. However, this was not the case with
the kidney. Moreover, in the small and large intestines,
which are also targets of Glu-P-1 carcinogenicity, the
radioactivity bound to macromolecules was very low.
In this study, the binding of radioactivity to DNA in
various organs was not measured. To determine the
correlation between the distribution of Glu-P-1 radio-
activity and target organs for carcinogenicity, the mod-
ifications ofDNA in different organs by Glu-P-1 should
be studied.
For further studies on the mechanisms of induction
ofintestinal tumors by Glu-P-1 in the rat, the excretion
of Glu-P-1 and its metabolites in the bile was investi-
gated. The bile duct was cannulated, and the bile was
collected after the intragastric administration of '4C-
Glu-P-1. As shown in Figure 2, under these conditions,
the excretion of radioactivity into the bile gradually
increased with time, reaching a plateau ofabout 60% of
the administered amount at 24 hr. The excretion into
the urine was about 20% at this time, and in the feces
the radioactivity was almost undetectable. The muta-
genic activity detectable in the bile with S. typhimu-
rium TA 98 with S9 mix also increased with time, but
that without S9 was only one thousandth of that with
S9 mix. The bile collected for 24 hr was extracted with
acetonitrile and applied to an HPLC column (Li-
Chroprep RP-8) and eluted with acetonitrile/water (40/
60, v/v). At least four peaks of radioactivity, named I
to IV in order of elution, were separated. Significant
mutagenicity with S9 mix was found only in peak IV.
Peak IV was further subjected to another HPLC with
an ODS column and elution with acetonitrile/water (30/
70, vlv). Two major peaks of radioactivity were ob-
served and those of the mutagenicity and OD254 coin-
cided with these radioactivity peaks. Based on the elu-
tion position and mass and 1H-NMR spectra, the
material eluted as a later peak (Peak IV-2) under this
condition was identified as unchanged Glu-P-1. The ma-
terial at the earlier peak (peak IV-1) showed m/z of240
on the mass spectrum, suggesting that it might be an
N-acetyl derivative ofGlu-P-1. Figure 3 shows that the
1H-NMR spectrum ofthis material coincided with that
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FIGURE 3. 1H-NMR spectra of peak IV-1 and chemically synthe-
sized N-acetyl-Glu-P-1.
ofN-acetyl-Glu-P-1 which was synthesized chemically.
The amounts of unchanged Glu-P-1 and N-acetyl-Glu-
P-1 in24-hr-bile were inboth cases 3 to 7% ofthatwhich
was administered to the rat. The mutagenic activities
ofchemically synthesized N-acetyl-Glu-P-1 were 12,800
and 740 revertants/,ug toward S. typhimurium TA 98
and TA 100 with S9 mix, respectively. These specific
activities were about one fourth those of Glu-P-1. No
mutagenicity was detected without S9 mix.
MuchlowermutagenicityofN-acetylderivativesthan
the parent compounds was also observed with Trp-P-2
and 2-aminofluorene (6). However, 2-acetylaminoflu-
orene, as 2-aminofluorene, is a well known carcinogen
which is also activated by N-hydroxylation and N-O-
acylation (32). Thus N-acetyl-Glu-P-1 excreted in the
bile may also work as a carcinogen through metabolic
activation similar to that for 2-acetylaminofluorene. It
is not known ifN-acetyl-Glu-P-1 and Glu-P-1 are acti-
vated inthe intestinal mucosal cells and act as intestinal
carcinogens. Their active metabolites formed in the
liver and transported through the bile orblood may also
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work at the intestinal mucosa. However, a high rate of
excretion of Glu-P-1 metabolites into the bile suggests
the importance of the metabolites in the bile to the
carcinogenicity of Glu-P-1 in the intestine.
Binding of Metabolites of Glu-P-1 to
Proteins in Erythrocytes and
Plasma
At 24 hr after a single administration of 14C-Glu-P-1
to rats, radioactivity which correspond to about 1% of
the total administered was detectable in the blood, and
this decreased with time. The blood was separated into
blood cellsandplasmaandtheradioactivity precipitated
with cold ethanol or trichloroacetic acid was counted.
The radioactivity in the fraction of plasma proteins
reached a maximum around 24 hr and decreased to a
nondetectable level 6 days later. In the blood cell frac-
tion also, the maximum level, which was almost the
same as that in the plasma protein fraction when nor-
malized to that per unit volume of blood, was found at
24 hr. However, the decrease in the activity was grad-
ual, and even 26 days later about half ofthe maximum
level remained. The decay curve ofthe radioactivity in
the blood cell fraction coincided with the lifetime eryth-
rocytes (33).
From the 24-hr blood, the plasma was obtained and
separated by gel filtration on Sephacryl S-300. Most of
the radioactivity was found to be eluted with serum
albumin. Some radioactivity was found also in fractions
of Ot2-macroglobulin and immunoglobulins.
Erythrocytes from the same blood sample were col-
lected and washed. Most of the radioactivity was re-
covered in the supernatant of the hemolysate. From
this supernatant, hemoglobin was crystallized (34), with
the recovery of 85% of both protein and radioactivity.
This hemoglobin was solubilized, and globin was sepa-
rated from heme (35). The radioactivity was mostly re-
covered intheglobinfraction. Globinwas separatedinto
its subunits by CM-cellulose column chromatography
(36), and it was found that most of radioactivity was
bound to the IB chains. Distribution of radioactivity
showed 21%, 47%, and 13% for I, Il and `1I chains,
respectively and only 6% and 5% for Ia and lot chains,
respectively. Under the conditions employed, the bind-
ing of Glu-P-1 metabolite to P chains was one molecule
per 300 to 650 molecules. The nature ofbinding ofGlu-
P-1 metabolite to P-globin chains and albumin is not
clear at present.
Binding of Glu-P-1 metabolite to hemoglobin and
serum proteins may occur during the passage of the
bloodthroughtheliver. Bindingto serumproteins, such
as albumin, secreted from the liver may also take place
inside hepatocytes where Glu-P-1 is activated. A pref-
erential binding ofGlu-P-1 metabolite to 13-globins may
be due to the presence ofreactive amino acid residue(s)
in the ,B chains in positions highly accessible to Glu-P-
1 metabolite. Such a preferential binding to 13-globin
has also been observed with simetryn sulfoxide, an in
vivo metabolite ofa herbicide simetryn, which modifies
the cysteine-125 residue of the rat ,3-globin chain (37).
Adduct formation with hemoglobin has also been re-
ported for various mutagens and carcinogens (38-42),
and the use of some ofthese adducts for the dosimetry
of exposure ofhumans to chemicals in the occupational
environment has been proposed (39,42).
Blood samples are easy to obtain and large amounts
of hemoglobin and albumin are available from a small
amount of blood. Thus, if a highly sensitive method to
measure the adducts of heterocyclic amines to these
proteins is developed like that for carcinogen-DNA ad-
ducts (43), it may serve as agood tool for the dosimetry
ofactual exposure ofhumans to the mutagenic and car-
cinogenic compounds in cooked foods.
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